STAAR Surgical Corp (STAA) - Forward Price-to-Revenue Multiple

staar.com (STAA) - corporate logo

The forward P/S of the business visualizes the valuation dynamics of STAAR Surgical Company (STAA), where the value 0.10 represents the current metric. The automation of lens production with minimal capital expenditures ensures excess profits. Ownership of unique implantable lens technologies guarantees high profitability of global sales. Narrow specialization is successfully offset by technological dominance and the rapid expansion of presence in the US and Asian markets.

STAA staar.com: Forward Price-to-Revenue Multiple in the range 07/04/2022 - 11/15/2026

STAAR Surgical - analytical breakdowns and key metrics (STAA)

- market price and analyst price targets:
- market capitalization indicators:
General company analysis:STAA (STAAR Surgical Co)
Original product of staar.com

The stability of implantable lens supplies for STAAR Surgical Company (STAA) directly determines the market value of its shares, as reflected in the company's expected P/S chart. This ratio compares current market capitalization with projected revenue for the following year, eliminating the volatility of quarterly reports. The calculation is based on the ratio of the business's market price to expected sales volume, measuring the premium for future growth. The upward trend confirms investor confidence in margins; however, excessive overvaluation creates risks of a correction.

Analysis of competing companies

Price-to-Projected Revenue Ratio Intuitive Surgical Inc ISRG|Forward P/S Multiple Danaher Corporation Inc. DHR|BDX - Price-to-Projected Revenue Ratio|STERIS plc (STE) - Forward Price-to-Revenue Multiple|WST: Forward P/S Multiple|Market Cap to Future Revenue Ratio Baxter International Inc. (BAX)|MASI (masimo.com) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Stevanato Group Corp STVN|Forward Price-to-Revenue Multiple TFX (Teleflex Inc)|Merit Medical - Market Cap to Projected Revenue|Envista Holdings - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio ICUI (ICU Medical Inc)|XRAY - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio LeMaitre Corp LMAT|ATRC: Forward P/S Multiple|Forward Price-to-Revenue Multiple ChromaDex Corporation|ZIMV (ZimVie Inc) - Forward P/S Multiple|Market Cap to Projected Revenue ANGO (AngioDynamics)|Price-to-Projected Revenue Ratio Cerus Corp (CERS)|TKNO: Future Price to Revenue|Price-to-Projected Revenue Ratio Monogram Technologies Inc. MGRM|Forward Price to Sales STSS|INFU - Price-to-Projected Revenue Ratio|Forward Price to Sales UTMD (Utah Medical Products Inc.)|KORU Medical Systems Inc. (KRMD) - Price-to-Projected Revenue Ratio|Nyxoah S.A. - Forward Price to Sales|Price-to-Projected Revenue Ratio Microbot Medical, Inc.|Market Cap to Projected Revenue PDEX (Pro-Dex)|Price-to-Projected Revenue Ratio Zentek (ZTEK)|Market Cap to Expected Sales Ratio Elutia Inc|Forward P/S Multiple MLSS (milestonescientific.com)|NXGL: Market Cap to Projected Revenue|Retractable Tech - Forward P/S Multiple|Market Cap to Expected Sales Ratio Harvard Bioscience Inc. HBIO|FEMY: Forward P/S Multiple|MeihuaMed - Forward Price to Sales|Price-to-Projected Revenue Ratio Predictive Oncology Inc|callanjmb.com (CJMB) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Atrion Corporation (ATRI)|Market Cap to Expected Sales Ratio neurometrix.com